603669 灵康药业
已收盘 04-30 15:00:00
资讯
新帖
简况
灵康药业04月30日获主力加仓2739.0万元
市场透视 · 04-30 07:21
灵康药业04月30日获主力加仓2739.0万元
灵康药业04月29日获主力加仓1224万元
市场透视 · 04-29 07:20
灵康药业04月29日获主力加仓1224万元
灵康药业涨5.12% 近半年1家券商增持
智选洞察 · 04-29 02:47
灵康药业涨5.12% 近半年1家券商增持
灵康药业乙酰唑胺缓释胶囊获临床试验批准,助力急性高山病预防
报告大厅 · 04-28 16:20
灵康药业乙酰唑胺缓释胶囊获临床试验批准,助力急性高山病预防
灵康药业:全资子公司获得乙酰唑胺缓释胶囊药物临床试验批准通知书
每日经济新闻 · 04-28 08:09
灵康药业:全资子公司获得乙酰唑胺缓释胶囊药物临床试验批准通知书
灵康药业(603669.SH)发布一季度业绩,归母净亏损1862万元
智通财经 · 04-25
灵康药业(603669.SH)发布一季度业绩,归母净亏损1862万元
图解灵康药业一季报:第一季度单季净利润同比减16.08%
证券之星 · 04-25
图解灵康药业一季报:第一季度单季净利润同比减16.08%
灵康药业一季度营收同比下降34.8% 亏损扩大至1862万元
财中社 · 04-25
灵康药业一季度营收同比下降34.8% 亏损扩大至1862万元
灵康药业:一季度净亏损1862.12万元
格隆汇 · 04-25
灵康药业:一季度净亏损1862.12万元
灵康药业大跌5% 近半年1家券商增持
智选洞察 · 04-25
灵康药业大跌5% 近半年1家券商增持
灵康药业2024年营收大增92.95%却难填亏损黑洞,三年累亏4.78亿,集采中标成“甜蜜负担”
金融界 · 04-25
灵康药业2024年营收大增92.95%却难填亏损黑洞,三年累亏4.78亿,集采中标成“甜蜜负担”
灵康药业04月24日主力净流入4073万元 散户资金抛售
市场透视 · 04-24
灵康药业04月24日主力净流入4073万元 散户资金抛售
4月24日灵康药业(603669)涨停分析:业绩改善、仿制药突破及CRO概念驱动
证券之星 · 04-24
4月24日灵康药业(603669)涨停分析:业绩改善、仿制药突破及CRO概念驱动
AI制药管线数量快速提升!上百个AI驱动的药物管线获批临床
制药网 · 04-24
AI制药管线数量快速提升!上百个AI驱动的药物管线获批临床
AACR即将开幕,医药或迎密集催化
Ofweek维科网 · 04-24
AACR即将开幕,医药或迎密集催化
【化学制药板块震荡走强,河化股份、灵康药业涨停】化学制药板块震荡走强,河化股份、灵康药业涨停,尔康制药涨超10%,罗欣药业、益方生物纷纷冲高。
金融界 · 04-24
【化学制药板块震荡走强,河化股份、灵康药业涨停】化学制药板块震荡走强,河化股份、灵康药业涨停,尔康制药涨超10%,罗欣药业、益方生物纷纷冲高。
A股化学制药板块震荡走强,河化股份、灵康药业涨停,尔康制药涨超10%,罗欣药业、益方生物纷纷冲高。
美港电讯 · 04-24
A股化学制药板块震荡走强,河化股份、灵康药业涨停,尔康制药涨超10%,罗欣药业、益方生物纷纷冲高。
美国关税或致药品短缺?行业警告:低利润仿制药面临停产危机
华尔街见闻 · 04-21
美国关税或致药品短缺?行业警告:低利润仿制药面临停产危机
灵康药业截止03月31日股东人数2.05万户,人均持股3.52万股
市场透视 · 04-21
灵康药业截止03月31日股东人数2.05万户,人均持股3.52万股
灵康药业涨5.69% 近半年1家券商增持
智选洞察 · 04-21
灵康药业涨5.69% 近半年1家券商增持
加载更多
公司概况
公司名称:
灵康药业集团股份有限公司
所属行业:
医药制造业
上市日期:
2015-05-28
主营业务:
灵康药业集团股份有限公司的主营业务是化药处方药的研发、生产和销售。公司的主要产品是奥美拉唑钠、注射用头孢美唑钠、注射用泮托拉唑钠、注射用氨曲南、注射用头孢呋辛钠、盐酸艾司洛尔注射液、盐酸多巴胺注射液、注射用拉氧头孢钠、丙氨酰谷氨酰胺注射液、氟马西尼注射液、注射用头孢唑肟钠、左卡尼汀注射液。公司先后获得“中国创新力医药企业”、“中国药品研发综合实力百强榜”等荣誉、灵康制药“一种奥美拉唑钠半水合物及其制备方法”专利荣获中国专利优秀奖,继续保持公司在行业内的竞争优势。
发行价格:
11.70
{"stockData":{"symbol":"603669","market":"SH","secType":"STK","nameCN":"灵康药业","latestPrice":4.52,"timestamp":1745996401000,"preClose":4.29,"halted":0,"volume":31339085,"delay":0,"changeRate":0.0536,"floatShares":721000000,"shares":721000000,"eps":-0.1849,"marketStatus":"已收盘","change":0.23,"latestTime":"04-30 15:00:00","open":4.37,"high":4.62,"low":4.19,"amount":140000000,"amplitude":0.1002,"askPrice":4.52,"askSize":309,"bidPrice":4.51,"bidSize":4943,"shortable":0,"etf":0,"ttmEps":-0.1849,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1746495000000},"marketStatusCode":5,"adr":0,"adjPreClose":4.29,"symbolType":"stock","openAndCloseTimeList":[[1745976600000,1745983800000],[1745989200000,1745996400000]],"highLimit":4.72,"lowLimit":3.86,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":721244755,"isCdr":false,"pbRate":4.72,"roa":"--","roe":"--","epsLYR":-0.18,"committee":0.479442,"marketValue":3260000000,"turnoverRate":0.0435,"status":0,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2025-05-06。","floatMarketCap":3260000000},"requestUrl":"/m/hq/s/603669","defaultTab":"news","newsList":[{"id":"2531072537","title":"灵康药业04月30日获主力加仓2739.0万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531072537","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531072537?lang=zh_cn&edition=full","pubTime":"2025-04-30 15:21","pubTimestamp":1745997702,"startTime":"0","endTime":"0","summary":"04月30日, 灵康药业股价涨5.36%,报收4.52元,成交金额1.4亿元,换手率4.35%,振幅10.02%,量比0.99。灵康药业今日主力资金净流入2739.0万元,连续3日净流入,上一交易日主力净流入1224.6万元。近一年数据显示,该股主力连续3日净流入后,次日上涨概率为46.15%,平均涨幅为5.05%。该股近5个交易日上涨7.62%,主力资金累计净流入6686.8万元,其中1个交易日为股价下跌时净流入;近20日主力资金累计净流入2190.3万元,其中净流入天数为6日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430165425a6ce9480&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430165425a6ce9480&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0033","BK0056","BK0239","603669"],"gpt_icon":0},{"id":"2531271642","title":"灵康药业04月29日获主力加仓1224万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531271642","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531271642?lang=zh_cn&edition=full","pubTime":"2025-04-29 15:20","pubTimestamp":1745911203,"startTime":"0","endTime":"0","summary":"04月29日, 灵康药业股价涨4.63%,报收4.29元,成交金额1.4亿元,换手率4.46%,振幅7.80%,量比1.01。灵康药业今日主力资金净流入1224万元,上一交易日主力净流入86万元。该股近5个交易日下跌1.83%,主力资金累计净流入1117万元;近20日主力资金累计净流出699万元,其中净流出天数为15日。|04月29日主力加仓幅度排名||#|股票简称|主力净额占比|#|红墙股份|7.84%|#|塞力医疗|6.27%|#|东珠生态|5.34%|#|...|...|#279|灵康药业|0.40%|灵康药业所在的化学制药行业,今日主力净流出5.20亿元,行业排名5/124。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429163323a46bc2db&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429163323a46bc2db&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","BK0033","603669","BK0056"],"gpt_icon":0},{"id":"2531210199","title":"灵康药业涨5.12% 近半年1家券商增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2531210199","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531210199?lang=zh_cn&edition=full","pubTime":"2025-04-29 10:47","pubTimestamp":1745894839,"startTime":"0","endTime":"0","summary":"04月29日,灵康药业股价大幅上涨,截至10点47分,灵康药业上涨5.12%,报4.31元/股,成交7282万元,换手率2.40%。此外,数据统计显示,近半年内1家券商给予增持建议。资金动向截止发稿,灵康药业获得主力净流入497万元,其中超大单流入414万元,大单流入82万元。最新财报显示,今年一季报,灵康药业实现营业收入5,012.11万元,同比减少34.79%,净利润为-1,862.12万元,同比减少16.08%,基本每股收益为-0.03元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429104724a46b5a75&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429104724a46b5a75&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0056","BK0239","BK0033","603669"],"gpt_icon":0},{"id":"2531252531","title":"灵康药业乙酰唑胺缓释胶囊获临床试验批准,助力急性高山病预防","url":"https://stock-news.laohu8.com/highlight/detail?id=2531252531","media":"报告大厅","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531252531?lang=zh_cn&edition=full","pubTime":"2025-04-29 00:20","pubTimestamp":1745857209,"startTime":"0","endTime":"0","summary":"灵康药业旗下全资子公司成功获得乙酰唑胺缓释胶囊的临床试验批准,这一突破标志着该药品在预防和改善急性高山病相关症状方面迈出了关键一步。灵康药业表示将积极推进乙酰唑胺缓释胶囊的研发项目,并及时披露项目进展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042902563494e643a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042902563494e643a8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0056","603669","BK0033","BK0239"],"gpt_icon":0},{"id":"2530288944","title":"灵康药业:全资子公司获得乙酰唑胺缓释胶囊药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2530288944","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530288944?lang=zh_cn&edition=full","pubTime":"2025-04-28 16:09","pubTimestamp":1745827757,"startTime":"0","endTime":"0","summary":"每经AI快讯,4月28日,灵康药业(603669.SH)公告称,公司全资子公司海南灵康制药有限公司于近日取得国家药品监督管理局药品审评中心签发的关于乙酰唑胺缓释胶囊的《药物临床试验批准通知书》。该药品适用于预防或改善逐步上升的情况下仍然会出现的急性高山病的相关症状。目前国内暂无其他企业对该产品进行申报,灵康制药已投入研发费用为690万人民币。每日经济新闻","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250428161205a46a1b5c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250428161205a46a1b5c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0033","BK0239","603669","BK0056"],"gpt_icon":0},{"id":"2530022339","title":"灵康药业(603669.SH)发布一季度业绩,归母净亏损1862万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530022339","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530022339?lang=zh_cn&edition=full","pubTime":"2025-04-25 18:17","pubTimestamp":1745576279,"startTime":"0","endTime":"0","summary":"智通财经APP讯,灵康药业(603669.SH)披露2025年第一季度报告,报告期公司实现营收5012万元,同比下降34.79%;归母净利润亏损1862万元;扣非净利润亏损1791万元。基本每股收益-0.03元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1285116.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0056","603669","BK0033"],"gpt_icon":0},{"id":"2530890908","title":"图解灵康药业一季报:第一季度单季净利润同比减16.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530890908","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530890908?lang=zh_cn&edition=full","pubTime":"2025-04-25 17:44","pubTimestamp":1745574297,"startTime":"0","endTime":"0","summary":"证券之星消息,灵康药业2025年一季报显示,公司主营收入5012.11万元,同比下降34.79%;归母净利润-1862.12万元,同比下降16.08%;扣非净利润-1791.49万元,同比上升12.27%;负债率39.0%,投资收益-334.65万元,财务费用500.5万元,毛利率28.03%。财报数据概要请见下图:以上内容为证券之星据公开信息整理,由智能算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042500031257.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603669"],"gpt_icon":0},{"id":"2530380907","title":"灵康药业一季度营收同比下降34.8% 亏损扩大至1862万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530380907","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530380907?lang=zh_cn&edition=full","pubTime":"2025-04-25 17:44","pubTimestamp":1745574269,"startTime":"0","endTime":"0","summary":"4月25日,灵康药业公布2025年一季报,公司营业收入为5012万元,同比下降34.8%;归母净利润自去年同期亏损1604万元变为亏损1862万元,亏损额进一步扩大;扣非归母净利润自去年同期亏损2042万元变为亏损1791万元,亏损额有所减少;经营现金流净额为-1357万元,同比增长34.4%;EPS为-0.0258元。报告期内,营业收入为5012万元,相较于上年同期下降了34.8%。文章来源:财中社灵康药业一季度营收同比下降34.8% 亏损扩大至1862万元","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425175941a6c7dd10&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425175941a6c7dd10&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["603669"],"gpt_icon":0},{"id":"2530790572","title":"灵康药业:一季度净亏损1862.12万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530790572","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530790572?lang=zh_cn&edition=full","pubTime":"2025-04-25 16:45","pubTimestamp":1745570724,"startTime":"0","endTime":"0","summary":"格隆汇4月25日丨灵康药业(603669.SH)公布2025年第一季度报告,报告期实现营业收入5012.11万元,同比下降34.79%;归属于上市公司股东的净利润-1862.12万元;基本每股收益-0.03元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425164524a4668b63&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425164524a4668b63&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["603669","BK0239","BK0033","BK0056"],"gpt_icon":0},{"id":"2530924113","title":"灵康药业大跌5% 近半年1家券商增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2530924113","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530924113?lang=zh_cn&edition=full","pubTime":"2025-04-25 14:22","pubTimestamp":1745562124,"startTime":"0","endTime":"0","summary":"04月25日,灵康药业股价大幅下跌,截至14点22分,灵康药业下跌5.19%,报4.38元/股,成交1.59亿元,换手率4.98%。此外,数据统计显示,近半年内1家券商给予增持建议。资金动向截止发稿,灵康药业获得主力净流出891万元,其中超大单流出1500万元,大单流入610万元。最新财报显示,今年年报,灵康药业实现营业收入3.80亿元,同比增长92.95%,净利润为-1.31亿元,同比增长13.68%,基本每股收益为-0.18元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425142225a6c79ceb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425142225a6c79ceb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","BK0033","BK0056","603669"],"gpt_icon":0},{"id":"2530810924","title":"灵康药业2024年营收大增92.95%却难填亏损黑洞,三年累亏4.78亿,集采中标成“甜蜜负担”","url":"https://stock-news.laohu8.com/highlight/detail?id=2530810924","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530810924?lang=zh_cn&edition=full","pubTime":"2025-04-25 14:05","pubTimestamp":1745561121,"startTime":"0","endTime":"0","summary":"营收激增难掩盈利困境,核心产品毛利率承压2024年,灵康药业营业收入实现近翻倍增长,主要得益于集采中标品种的市场放量。财报显示,2024年其心脑血管类产品以14.05亿元收入贡献了38%的营收,同比激增319.07%;抗感染类产品收入同比增长59.92%,达1.58亿元。尽管灵康药业强调“精细化管理”,但营业成本同比增幅达92.19%,几乎与营收增速持平。尤其是抗感染类产品的营业成本飙升92.69%,远超收入增速,导致该品类毛利率跌至个位数。","market":"hk","thumbnail":"http://imgcloud.jrjimg.cn/2025/04/25/7b6c957450e94b7fe55fcb7e62d142f1.png","type":0,"news_type":0,"thumbnails":["http://imgcloud.jrjimg.cn/2025/04/25/7b6c957450e94b7fe55fcb7e62d142f1.png"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/25140549870450.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["603669"],"gpt_icon":0},{"id":"2529675102","title":"灵康药业04月24日主力净流入4073万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2529675102","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529675102?lang=zh_cn&edition=full","pubTime":"2025-04-24 15:23","pubTimestamp":1745479396,"startTime":"0","endTime":"0","summary":"04月24日, 灵康药业股价涨10.00%,报收4.62元,成交金额9148万元,换手率2.81%,振幅9.52%,量比1.29。灵康药业今日主力资金净流入4073万元,上一交易日主力净流出2831万元。该股近5个交易日上涨14.93%,主力资金累计净流入2151万元;近20日主力资金累计净流出713万元,其中净流出天数为15日。|04月24日主力加仓幅度排名||#|股票简称|主力净额占比|#|N天有|22.97%|#|N江顺科技|15.83%|#|金凯生科|7.71%|#|...|...|#56|灵康药业|1.22%|灵康药业所在的化学制药行业,今日主力净流入2.98亿元,行业排名3/124。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250424165225a6c652ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250424165225a6c652ab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["603669","BK0056","BK0239","BK0033"],"gpt_icon":0},{"id":"2529625256","title":"4月24日灵康药业(603669)涨停分析:业绩改善、仿制药突破及CRO概念驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2529625256","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529625256?lang=zh_cn&edition=full","pubTime":"2025-04-24 15:22","pubTimestamp":1745479321,"startTime":"0","endTime":"0","summary":"证券之星消息,灵康药业4月24日涨停收盘,收盘价4.62元。今日灵康药业涨停的可能因素有:1)公司2024年营业收入同比增长92.95%,亏损幅度显著收窄,基本面改善预期增强;2)全资子公司注射用维库溴铵通过仿制药一致性评价,强化产品竞争力;3)CRO概念板块整体走强,带动市场情绪;4)抗感染药物产品在春季流感高发期需求提升;5)西藏区域政策红利及仿制药政策支持形成长期概念支撑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042400020342.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603669","BK0033","BK0239","BK0056"],"gpt_icon":0},{"id":"2529793817","title":"AI制药管线数量快速提升!上百个AI驱动的药物管线获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2529793817","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529793817?lang=zh_cn&edition=full","pubTime":"2025-04-24 14:57","pubTimestamp":1745477831,"startTime":"0","endTime":"0","summary":"自 AI 技术开始应用于药物研发以来,AI 驱动的药物管线数量呈现出爆发式增长。如今,全球范围内已有 102 个 AI 驱动的药物管线获批临床试验,其中56个处于Ⅰ期、41个处于Ⅱ期、5个处于Ⅲ期,涵盖了多种疾病领域,包括肿瘤、神经系统疾病、心血管疾病等。一些用于治疗心律失常、心力衰竭等心血管疾病的 AI 驱动药物管线,正在临床试验中接受进一步验证,有望为心血管疾病患者提供更有效的治疗方案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042414581494e09c56&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042414581494e09c56&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600851","688578","600420","688566","600216","603351","601089","BK0168","600380","605507","600812","603538","600789","688117","BK0046","688658","688076","600062","603669","603367","688799","600267","600521","603676","BK0239","600488","BK0188","605116"],"gpt_icon":0},{"id":"2529462576","title":"AACR即将开幕,医药或迎密集催化","url":"https://stock-news.laohu8.com/highlight/detail?id=2529462576","media":"Ofweek维科网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529462576?lang=zh_cn&edition=full","pubTime":"2025-04-24 11:19","pubTimestamp":1745464762,"startTime":"0","endTime":"0","summary":"AACR将于当地时间4月25日至4月30日在美国费城召开,本次会议将有近100家中国药企亮相,带来超200项新药研究结果。恒瑞医药、科伦博泰、信达生物、百利天恒、再鼎医药、复宏汉霖、乐普生物等有望发布重要ADC数据,涉及诸多靶点,中国ADC技术有望在国际舞台崭露头角。近年来,国内创新药在AACR会议上的影响力持续攀升,ADC之外,双抗及小分子疗法市场关注度也较高,或带来更多消息面的催化,恒生医药ETF已连续5日上涨。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504241119259742f8a7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504241119259742f8a7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0012","BK0196","600812","600216","601089","603367","BK0060","BK0183","688076","688799","688506","600196","688578","605507","603676","600488","603351","688602","BK0096","603538","159938","BK0188","600062","688505","600789","600420","600521","BK0028","600267","600664","688166","688658","605116","603669","BK0239","688247","BK0187","600380","688566","BK0175","688091"],"gpt_icon":0},{"id":"2529618390","title":"【化学制药板块震荡走强,河化股份、灵康药业涨停】化学制药板块震荡走强,河化股份、灵康药业涨停,尔康制药涨超10%,罗欣药业、益方生物纷纷冲高。","url":"https://stock-news.laohu8.com/highlight/detail?id=2529618390","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529618390?lang=zh_cn&edition=full","pubTime":"2025-04-24 09:44","pubTimestamp":1745459060,"startTime":"0","endTime":"0","summary":"化学制药板块震荡走强,河化股份、灵康药业涨停,尔康制药涨超10%,罗欣药业、益方生物纷纷冲高。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/24094449815496.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0033","688382","BK0132","01477","BK0066","BK1191","BK0056","BK0071","BK0239","BK0201","BK0028","000953","002793","300267","BK0010","BK0001","BK0004","BK1574","08058","BK0077","603669"],"gpt_icon":0},{"id":"2529690763","title":"A股化学制药板块震荡走强,河化股份、灵康药业涨停,尔康制药涨超10%,罗欣药业、益方生物纷纷冲高。","url":"https://stock-news.laohu8.com/highlight/detail?id=2529690763","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529690763?lang=zh_cn&edition=full","pubTime":"2025-04-24 09:43","pubTimestamp":1745458981,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["159982","BK0001","BK0004","08058","BK0071","BK0239","BK0201","BK0056","300267","BK1191","BK1574","BK0010","000953","BK0033","BK0077","603669","688382","002793","BK0066","399300","01477","BK0132","BK0028"],"gpt_icon":0},{"id":"2529809163","title":"美国关税或致药品短缺?行业警告:低利润仿制药面临停产危机","url":"https://stock-news.laohu8.com/highlight/detail?id=2529809163","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529809163?lang=zh_cn&edition=full","pubTime":"2025-04-21 18:06","pubTimestamp":1745230017,"startTime":"0","endTime":"0","summary":"特朗普口中的“关税武器”,瞄准了全球仰赖的仿制药供应链。据央视新闻,美国或对进口药品征收关税。特朗普多次放话,药品可能被纳入征税范围。本周,美国商务部也宣布对药品进口是否构成“国家安全风险”启动调查。要知道,仿制药承担了美国约90%的药品供应,本身利润就极其微薄,加征关税一旦成真,部分药企或直接停产。目前美国大部分仿制药产自印度和东南亚,美国很难自给自足。事实上,美国药品供应紧张早已有苗头。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250421180725a6c227a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250421180725a6c227a8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688799","600079","600521","688566","688758","603669","688578","603351","605116","603538","600267","688506","688321","603168","600624","600789","600613","603676","600812","688247","688076","603207","600774","603811","688166","688513","603707","600276","BK0239","688356","600664","603229"],"gpt_icon":0},{"id":"2529112823","title":"灵康药业截止03月31日股东人数2.05万户,人均持股3.52万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2529112823","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529112823?lang=zh_cn&edition=full","pubTime":"2025-04-21 15:19","pubTimestamp":1745219968,"startTime":"0","endTime":"0","summary":"灵康药业披露公司股东人数最新情况,截止2025年03月31日,公司股东人数为2.05万户,较上期增加3916户,环比增长9.61%。在化学制药行业个股中,灵康药业股东户数少于行业平均水平,截至2025年03月31日,化学制药行业平均股东户数为3.4万户,户均持股市值方面,化学制药行业A股上市公司户均持股市值为72.01万元,灵康药业少于行业平均水平。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250421154720a460a609&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250421154720a460a609&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["603669","BK0033","BK0239","BK0056"],"gpt_icon":0},{"id":"2529634819","title":"灵康药业涨5.69% 近半年1家券商增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2529634819","media":"智选洞察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529634819?lang=zh_cn&edition=full","pubTime":"2025-04-21 09:39","pubTimestamp":1745199561,"startTime":"0","endTime":"0","summary":"04月21日,灵康药业股价大幅上涨,截至09点39分,灵康药业上涨5.69%,报4.27元/股,成交1102万元,换手率0.37%,振幅6.68%。此外,数据统计显示,近半年内1家券商给予增持建议。资金动向截止发稿,灵康药业获得主力净流入144万元。主营业务及业绩灵康药业公司主营业务为化药处方药的研发、生产和销售。最新财报显示,今年年报,灵康药业实现营业收入3.80亿元,同比增长92.95%,净利润为-1.31亿元,同比增长13.68%,基本每股收益为-0.18元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042109395294dc48e1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042109395294dc48e1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0033","BK0239","BK0056","603669"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1746066223261,"stockEarnings":[{"period":"1week","weight":0.0762},{"period":"1month","weight":0.0439},{"period":"3month","weight":-0.1691},{"period":"6month","weight":-0.1986},{"period":"1year","weight":-0.0444},{"period":"ytd","weight":-0.139}],"compareEarnings":[{"period":"1week","weight":-0.0053},{"period":"1month","weight":-0.017},{"period":"3month","weight":0.0087},{"period":"6month","weight":0.0021},{"period":"1year","weight":0.0561},{"period":"ytd","weight":-0.0217}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"灵康药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"20516人(较上一季度增加9.61%)","perCapita":"35155股","listingDate":"2015-05-28","address":"西藏自治区山南市乃东区国道349号(结巴乡段)20号","registeredCapital":"72124万元","survey":" 灵康药业集团股份有限公司的主营业务是化药处方药的研发、生产和销售。公司的主要产品是奥美拉唑钠、注射用头孢美唑钠、注射用泮托拉唑钠、注射用氨曲南、注射用头孢呋辛钠、盐酸艾司洛尔注射液、盐酸多巴胺注射液、注射用拉氧头孢钠、丙氨酰谷氨酰胺注射液、氟马西尼注射液、注射用头孢唑肟钠、左卡尼汀注射液。公司先后获得“中国创新力医药企业”、“中国药品研发综合实力百强榜”等荣誉、灵康制药“一种奥美拉唑钠半水合物及其制备方法”专利荣获中国专利优秀奖,继续保持公司在行业内的竞争优势。","listedPrice":11.7},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"灵康药业(603669)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供灵康药业(603669)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"灵康药业,603669,灵康药业股票,灵康药业股票老虎,灵康药业股票老虎国际,灵康药业行情,灵康药业股票行情,灵康药业股价,灵康药业股市,灵康药业股票价格,灵康药业股票交易,灵康药业股票购买,灵康药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"灵康药业(603669)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供灵康药业(603669)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}